Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically

MLA

Mariaserena Giliberto, et al. “Ex Vivo Drug Sensitivity Screening in Multiple Myeloma Identifies Drug Combinations That Act Synergistically.” Molecular Oncology, vol. 16, no. 6, Mar. 2022, pp. 1241–58. EBSCOhost, https://doi.org/10.1002/1878-0261.13191.

APA

Mariaserena Giliberto, Deepak B. Thimiri Govinda Raj, Andrea Cremaschi, Sigrid S. Skånland, Alexandra Gade, Geir E. Tjønnfjord, Fredrik Schjesvold, Ludvig A. Munthe, & Kjetil Taskén. (2022). Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. Molecular Oncology, 16(6), 1241–1258. https://doi.org/10.1002/1878-0261.13191

Chicago

Mariaserena Giliberto, Deepak B. Thimiri Govinda Raj, Andrea Cremaschi, Sigrid S. Skånland, Alexandra Gade, Geir E. Tjønnfjord, Fredrik Schjesvold, Ludvig A. Munthe, and Kjetil Taskén. 2022. “Ex Vivo Drug Sensitivity Screening in Multiple Myeloma Identifies Drug Combinations That Act Synergistically.” Molecular Oncology 16 (6): 1241–58. doi:10.1002/1878-0261.13191.